Research programme: vaccines - Cytos Biotechnology

Drug Profile

Research programme: vaccines - Cytos Biotechnology

Alternative Names: C5aQb; CCR5Qb; CYT015-M2AP; CYT017-IL17Qb; DENAP; IL17Qb; IL1aQb; IL5Qb; IL6Qb; MIFQb

Latest Information Update: 13 May 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cytos Biotechnology
  • Class Virus-like particle vaccines
  • Mechanism of Action Cytokine modulators; Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Inflammation; Multiple sclerosis; Psoriasis
  • No development reported Dengue; HIV infections
  • Discontinued Atherosclerosis; Cancer; Creutzfeldt-Jakob disease; Hepatitis B; Hypersensitivity; Osteoporosis; Systemic lupus erythematosus

Most Recent Events

  • 13 May 2014 Research programme: vaccines - Cytos Biotechnology is available for licensing as of 05 May 2014. http://www.cytos.com
  • 18 Aug 2011 Suspended - Preclinical for Inflammation in Switzerland (unspecified route)
  • 18 Aug 2011 Suspended - Preclinical for Multiple sclerosis in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top